Compare DAN & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAN | RCUS |
|---|---|---|
| Founded | 1904 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 2.8B |
| IPO Year | 1998 | 2018 |
| Metric | DAN | RCUS |
|---|---|---|
| Price | $36.34 | $22.36 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 11 |
| Target Price | ★ $36.80 | $30.27 |
| AVG Volume (30 Days) | ★ 1.1M | 892.5K |
| Earning Date | 04-29-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.33% | N/A |
| EPS Growth | ★ 264.10 | N/A |
| EPS | ★ 0.64 | N/A |
| Revenue | ★ $7,500,000,000.00 | $247,000,000.00 |
| Revenue This Year | $1.77 | N/A |
| Revenue Next Year | $4.02 | $83.23 |
| P/E Ratio | $56.56 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.61 | $7.06 |
| 52 Week High | $36.48 | $26.40 |
| Indicator | DAN | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 66.47 | 51.85 |
| Support Level | $18.71 | $20.18 |
| Resistance Level | N/A | $24.33 |
| Average True Range (ATR) | 1.14 | 1.09 |
| MACD | 0.34 | 0.11 |
| Stochastic Oscillator | 93.73 | 66.52 |
Dana Inc is engaged in the designing and manufacturing of efficient propulsion and energy-management solutions that power vehicles and machines in all mobility markets across the globe. The company has four operating segments: Light Vehicles, Power Technologies, Commercial Vehicle, and Off-Highway. The Light Vehicles segment generates the majority portion of revenue by providing products to support light vehicle OEMs. Its products are designed for light trucks, SUVs, CUVs, vans, and passenger cars.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.